Cancer Gene Therapy Market Size, Share, Opportunities, And Trends By Therapy Type (Immunotherapy, Oncolytic Virotherapy, Gene Transfer, Others), By Vector Type (Viral, Non-Viral, Cell-Based Carrier), By Cancer Type (Breast, Lung, Pancreas, Prostate, Others), By End User (Hospitals & Clinics, Diagnostic & Research Institutes, Others), And By Geography - Forecasts From 2025 To 2030

Cancer Gene Therapy Market Size:

The cancer gene therapy market is expected to grow from US$3.484 billion in 2025 to US$8.561 billion in 2030, at a CAGR of 19.70%.

Cancer Gene Therapy Market Trends:

The rise in investment in cancer gene therapy research and development, together with the growing incidence of cancer, are the main drivers of the cancer gene therapy market's expansion.

According to data published by the Open Government Data (OGD) Platform India, cancer cases have increased in recent years. In the year 2019, people suffering from cancer were 13,58,415 in India, which rose to 14,61,427 cancer cases in 2022. A considerable need for innovative therapeutic medications that could be useful for cancer therapy is predicted due to the rising incidence of cancer patients. Conventional gene treatments target the immune system to improve remissions for patients with advanced-stage tumors due to the rising importance of immunotherapy in cancer treatment.

Cancer Gene Therapy Market Growth Drivers:

• Increasing Research And Development Activities

Top market players are concentrating on R&D and regional growth tactics for greater market penetration. As per the WHO data published in April 2023, the total gross domestic spending on research and development for healthcare as % of GDP was 0.07% for Western specific which is leading the market, America was 0.03% and for Eastern Mediterranean, it was just 0.01% of the total GDP.

Further, in August 2022, the FDA approved Bluebird Bio's BLUE.O gene therapy for use in the treatment of patients with a rare condition that needs routine blood transfusions. Each unit of the medication costs USD 2.8 million. 

Oncolytic virotherapy research is supported by several highly attractive grants. For instance, the National Institutes of Health awarded the researchers at the Centre for Nuclear Receptors and Cell Signalling at the University of Houston a USD 1.8 million grant in July 2022 to study oncolytic virotherapy.  Additionally, in June 2022, the phase 1 clinical trials for ImmunoAct's CAR-T (chimeric antigen receptor) therapy, which is used to treat certain forms of cancer were completed.

Elicera Therapeutics AB, a cell and gene therapy firm in clinical development, received financing from the European Innovation Council (EIC) Accelerator Programme in June 2022 for $2.67 million (€2.5 million). The market for cancer gene therapy is predicted to benefit significantly from rising medical funding. In December 2022, researchers in the UK treated a young kid with relapsed T-cell leukemia using a novel sort of gene therapy. The use of this novel gene therapy has sparked expectations that it can treat major illnesses as well as other types of pediatric cancer.

Cancer Gene Therapy Market Geographical Outlook:

• The United States in North America is an Expected Dominant Market

Cancer is one of the leading causes of death in the United States. In 2022, an estimated 1.9 million new cancer cases will be diagnosed in the United States, and 609,000 people will die from cancer. The increasing incidence of cancer is driving the demand for new and innovative cancer treatments, such as gene therapy. Consequently, significant advances in gene therapy technology have occurred in recent years. These advances have made it possible to develop gene therapy treatments for a wider range of cancers. For example, in 2022, the FDA granted approval for Adstiladrin (nadofaragene firadenovec-vncg), an adenoviral vector-mediated gene therapy. It is intended for adults experiencing high-risk Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle-invasive bladder cancer (NMIBC) presenting with carcinoma in situ (CIS), with or without accompanying papillary tumors.

Moreover, there is a growing investment in gene therapy research in the United States. This investment is being driven by the potential of gene therapy to cure cancer and other diseases. In 2022, the National Institutes of Health (NIH) awarded over $1 billion in funding for gene therapy research.

Further driving this momentum is the favorable regulatory environment. The regulatory environment for gene therapy is generally favorable in the United States. The FDA has approved several gene therapy treatments for cancer, and it is expected to approve more in the coming years.

The escalating figures of new cancer cases in the USA from 2020 to 2022—18,06,590 to 18,98,160 to 19,18,030—underscore the persistent and concerning prevalence of cancer. This trend accentuates the significance of advancements in cancer treatments, including gene therapy. The mounting need for innovative therapeutic interventions aligns with the potential growth of the cancer gene therapy market in the USA. As the patient pool expands, there is a concurrent opportunity for the development and adoption of gene therapies targeting various types of cancer, potentially reshaping the landscape of cancer treatment strategies in the coming years.

Cancer Gene Therapy Market Key Developments:

• In October 2022, Xcell Biosciences and aCGT Vector agreed to work together to manufacture and test cell and gene treatments for cancer patients.
• In June 2021, Tata Memorial Centre and Indian Institute of Technology researchers worked together to create "Chimeric Antigen Receptor T-cell," a cutting-edge kind of gene therapy for the treatment of cancer.
• Further, in December 2022, Adstiladrin, a non-replicating adenoviral vector-based gene therapy, received FDA approval. It is indicated for treating adult patients with high-risk, Bacillus Calmette-Guérin (BCG)-refractory, non-muscle-invasive bladder cancer (NMIBC), with carcinoma in situ (CIS), with or without papillary tumors.
• The FDA authorized Vyjuvek in May 2023 for the treatment of wounds in patients 6 months and older with dystrophic epidermolysis bullosa (DEB) and mutations in the collagen type VII alpha 1 chain (COLTA1) gene. Vyjuvek is a herpes simplex virus type 1 (HSV-1) vector-based gene therapy.
• In April 2023, REGENXBIO Inc. stated that the FDA had awarded RGX-202, a potential one-time gene therapy for the treatment of Duchenne muscular dystrophy.

Segmentation:

• By Therapy Type
  • Immunotherapy
  • Oncolytic Virotherapy
  • Gener Transfer
  • Others
• By Vector Type
• • Viral
  • Non-Viral
  • Cell-based
• By Cancer Type

• • Breast
  • Lungs
  • Pancreas
  • Prostate
  • Others
• By End-User
  • Hospitals & Clinics
  • Diagnostic & Research Institutes
  • Others

• By Geography
• • North America

• • • United States
    • Canada
    • Mexico
  • South America

• • • Brazil
    • Argentina
    • Others
  • Europe

• • • United Kingdom
    • Germany
    • France
    • Spain
    • Others

• • The Middle East and Africa

• • • Saudi Arabia
    • UAE
    • Israel
    • Others

• • Asia Pacific

• • • Japan
    • China
    • India
    • South Korea
    • Indonesia
    • Thailand
    • Others

---

1. INTRODUCTION

1.1. Market Overview

1.2. Market Definition

1.3. Scope of the Study

1.4. Market Segmentation

1.5. Currency

1.6. Assumptions

1.7. Base, and Forecast Years Timeline

2. RESEARCH METHODOLOGY  

2.1. Research Data

2.2. Sources

2.3. Research Design

3. EXECUTIVE SUMMARY

3.1. Research Highlights

4. MARKET DYNAMICS

4.1. Market Drivers

4.2. Market Restraints

4.3. Porter’s Five Forces Analysis

4.3.1. Bargaining Power of Suppliers

4.3.2. Bargaining Power of Buyers

4.3.3. Threat of New Entrants

4.3.4. Threat of Substitutes

4.3.5. Competitive Rivalry in the Industry

4.4. Industry Value Chain Analysis

5. CANCER GENE THERAPY MARKET, BY THERAPY TYPE

5.1. Introduction

5.2. Immunotherapy

5.3. Oncolytic Virotherapy

5.4. Gener Transfer

5.5. Others

6. CANCER GENE THERAPY MARKET, BY VECTOR TYPE

6.1. Introduction

6.2. Viral

6.3. Non-Viral

6.4. Cell-based Carrier

7. CANCER GENE THERAPY MARKET, BY CANCER TYPE

7.1. Introduction

7.2. Breast

7.3. Lungs

7.4. Pancreas

7.5. Prostate

7.6. Others

8. CANCER GENE THERAPY MARKET, BY END-USER

8.1. Introduction

8.2. Hospitals & Clinics

8.3. Diagnostic & Research Institutes

8.4. Others

9. CANCER GENE THERAPY MARKET, BY GEOGRAPHY

9.1. Introduction

9.2. North America

9.2.1. By Therapy Type

9.2.2. By Vector Type

9.2.3. By Cancer Type

9.2.4. By End-User

9.2.5. By Country

9.2.5.1. United States

9.2.5.2. Canada

9.2.5.3. Mexico

9.3. South America

9.3.1. By Therapy Type

9.3.2. By Vector Type

9.3.3. By Cancer Type

9.3.4. By End-User

9.3.5. By Country

9.3.5.1. Brazil

9.3.5.2. Argentina 

9.3.5.3. Others

9.4. Europe

9.4.1. By Therapy Type

9.4.2. By Vector Type

9.4.3. By Cancer Type

9.4.4. By End-User

9.4.5. By Country

9.4.5.1. Germany

9.4.5.2. France

9.4.5.3. United Kingdom

9.4.5.4. Italy

9.4.5.5. Spain

9.4.5.6. Others

9.5. Middle East and Africa

9.5.1. By Therapy Type

9.5.2. By Vector Type

9.5.3. By Cancer Type

9.5.4. By End-User

9.5.5. By Country

9.5.5.1. Saudi Arabia

9.5.5.2. Israel

9.5.5.3. United Arab Emirates

9.5.5.4. Others

9.6. Asia Pacific

9.6.1. By Therapy Type

9.6.2. By Vector Type

9.6.3. By Cancer Type

9.6.4. By End-User

9.6.5. By Country

9.6.5.1. China

9.6.5.2. Japan

9.6.5.3. South Korea

9.6.5.4. India

9.6.5.5. Australia

9.6.5.6. Indonesia

9.6.5.7. Thailand

9.6.5.8. Taiwan

9.6.5.9. Others

10. COMPETITIVE ENVIRONMENT AND ANALYSIS

10.1. Major Players and Strategy Analysis

10.2. Market Share Analysis

10.3. Mergers, Acquisitions, Agreements, and Collaborations

10.4. Vendor Competitiveness Matrix

11. COMPANY PROFILES

11.1. Shanghai Sunway Biotech Co. Ltd

11.2. Amgen Inc.

11.3. Novartis

11.4. Gilead Sciences, Inc.

11.5. Bluebirdbio, Inc

11.6. Celgene Inc

11.7. GlaxoSmithKline plc

11.8. ElevateBio

11.9. Kite Pharma

11.10. Synbio Technologies

Shanghai Sunway Biotech Co. Ltd

Amgen Inc.

Novartis

Gilead Sciences, Inc.

Bluebirdbio, Inc

Celgene Inc

GlaxoSmithKline plc

ElevateBio

Kite Pharma

Synbio Technologies